Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free EHTH Stock Alerts

eHealth (EHTH) Financials

eHealth logo
$0.41 -0.03 (-5.95%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.44 +0.02 (+5.12%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for eHealth

Annual Income Statements for eHealth

This table shows eHealth's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.76 0.30 25 0.24 67 45 -123 -119 -67 -35 -10
Consolidated Net Income / (Loss)		 -4.76 0.30 25 0.24 67 45 -104 -89 -28 10 40
Net Income / (Loss) Continuing Operations		 -4.76 0.30 25 0.24 67 45 -104 -89 -28 10 40
Total Pre-Tax Income 		-5.61 3.97 -8.27 3.31 83 54 -125 -106 -31 19 59
Total Revenue		 190 193 191 251 506 583 537 398 442 521 543
Net Interest Income / (Expense)		 0.00 0.00 0.00 0.00 0.00 0.00 -0.85 -7.63 -11 -11 -11
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.85 7.63 11 11 11
Long-Term Debt Interest Expense		 - - - - - - 0.85 7.63 11 11 11
Total Non-Interest Income		 190 193 191 251 506 583 538 405 453 532 554
Other Non-Interest Income		 - - 191 251 506 - 538 - 453 532 554
Total Non-Interest Expense		 195 191 200 249 425 529 664 508 482 509 488
Marketing Expense		 76 72 66 83 150 209 271 195 173 193 181
Other Operating Expenses		 114 118 133 150 248 319 341 293 309 307 304
Impairment Charge		 - - - - - 0.00 51 20 0.00 9.48 2.01
Nonoperating Income / (Expense), net		 0.05 1.15 1.18 0.76 2.09 - 1.60 3.95 9.45 6.90 3.00
Income Tax Expense		 -0.84 3.67 -34 3.07 17 8.54 -21 -18 -2.38 9.26 19
Preferred Stock Dividends Declared		 - - - - 0.00 0.00 19 31 38 45 50
Basic Earnings per Share		 ($0.26) $0.02 $1.37 $0.01 $2.90 $1.75 ($4.59) ($4.36) ($2.37) ($1.19) ($0.34)
Weighted Average Basic Shares Outstanding		 18.01M 18.27M 18.51M 19.29M 23.08M 26.03M 26.78M 27.36M 28.02M 29.34M 30.48M
Diluted Earnings per Share		 ($0.26) $0.02 $1.33 $0.01 $2.73 $1.68 ($4.59) ($4.36) ($2.37) ($1.19) ($0.34)
Weighted Average Diluted Shares Outstanding		 18.01M 18.31M 19.05M 20.41M 24.54M 27.01M 26.78M 27.36M 28.02M 29.34M 30.48M
Weighted Average Basic & Diluted Shares Outstanding		 18.30M 18.10M 18.50M 22.55M 23.46M 25.93M 26.77M 27.61M 28.94M 29.94M 31.07M

Quarterly Income Statements for eHealth

This table shows eHealth's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -28 -39 -54 86 -9.97 -30 -45 74 -18 -38 -50
Consolidated Net Income / (Loss)		 -17 -28 -42 97 1.95 -17 -32 87 -4.71 -24 -36
Net Income / (Loss) Continuing Operations		 -17 -28 -42 97 1.95 -17 -32 87 -4.71 -24 -36
Total Pre-Tax Income 		-18 -28 -44 110 3.73 -24 -43 122 -6.07 -31 -50
Total Revenue		 90 63 56 313 110 58 51 323 84 30 17
Net Interest Income / (Expense)		 -2.81 -2.85 -2.86 -2.64 -2.65 -2.35 -2.38 -3.38 -4.04 -4.05 -4.18
Total Interest Income		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Interest Expense		 2.81 2.85 2.86 2.64 2.65 2.35 2.38 3.38 4.04 4.05 4.18
Long-Term Debt Interest Expense		 2.81 2.85 2.86 2.64 2.65 2.35 2.38 3.38 4.04 4.05 4.18
Total Non-Interest Income		 93 66 58 315 113 61 54 326 88 34 21
Net Realized & Unrealized Capital Gains on Investments		 - - 58 - - - - - - - 21
Total Non-Interest Expense		 111 94 102 203 108 84 95 200 91 61 68
Marketing Expense		 39 27 30 96 41 21 24 94 25 12 11
Other Operating Expenses		 66 64 72 107 67 61 71 106 59 49 57
Impairment Charge		 6.31 3.04 0.06 0.07 0.00 1.56 0.46 - 6.37 0.06 0.00
Nonoperating Income / (Expense), net		 2.39 2.34 1.70 0.48 1.58 1.34 0.98 -0.90 0.84 0.83 0.79
Income Tax Expense		 -1.35 -0.51 -1.89 13 1.78 -6.65 -11 35 -1.36 -7.08 -14
Preferred Stock Dividends Declared		 11 11 11 12 12 12 13 13 13 14 14
Basic Earnings per Share		 ($0.96) ($1.33) ($1.83) $2.93 ($0.33) ($0.98) ($1.46) $2.43 ($0.58) ($1.18) ($1.57)
Weighted Average Basic Shares Outstanding		 28.91M 29.23M 29.49M 29.34M 30.00M 30.40M 30.63M 30.48M 31.13M 31.78M 32.13M
Diluted Earnings per Share		 ($0.96) ($1.33) ($1.83) $2.93 ($0.33) ($0.98) ($1.46) $2.43 ($0.58) ($1.18) ($1.57)
Weighted Average Diluted Shares Outstanding		 28.91M 29.23M 29.49M 29.34M 30.00M 30.40M 30.63M 30.48M 31.13M 31.78M 32.13M
Weighted Average Basic & Diluted Shares Outstanding		 29.12M 29.41M 29.63M 29.94M 30.33M 30.56M 30.76M 31.07M 31.74M 32.03M 32.36M

Annual Cash Flow Statements for eHealth

This table details how cash moves in and out of eHealth's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 11 -0.93 -21 -27 14 20 38 62 -29 -77 35
Net Cash From Operating Activities		 14 4.08 -16 -3.23 -71 -108 -163 -27 -6.69 -18 -25
Net Cash From Continuing Operating Activities		 18 4.05 -16 -3.23 -71 -108 -163 -27 -6.69 -18 -25
Net Income / (Loss) Continuing Operations		 0.00 0.30 25 0.24 67 45 -104 -89 -28 10 40
Consolidated Net Income / (Loss)		 - -0.30 25 0.24 67 45 -104 -89 -28 10 40
Depreciation Expense		 4.10 3.54 2.84 2.48 2.98 3.69 5.43 3.85 2.54 1.98 1.88
Amortization Expense		 3.76 1.94 2.50 4.29 6.01 9.25 13 17 17 14 12
Non-Cash Adjustments to Reconcile Net Income		 7.11 -2.47 -21 26 62 35 59 16 21 37 36
Changes in Operating Assets and Liabilities, net		 3.42 1.38 -26 -36 -209 -201 -136 25 -20 -82 -115
Net Cash From Investing Activities		 -3.00 -3.73 -5.08 -26 -17 -73 -13 26 -16 -48 25
Net Cash From Continuing Investing Activities		 -3.00 -3.73 -5.08 -26 -17 -73 -13 26 -16 -48 25
Purchase of Property, Leasehold Improvements and Equipment		 -3.00 -3.73 -5.08 -11 -17 -24 -21 -16 -11 -13 -15
Purchase of Investment Securities		 - 0.00 0.00 0.00 -0.07 -181 -103 -8.40 -55 -97 -74
Sale and/or Maturity of Investments		 - - - 0.00 0.00 131 111 50 49 61 115
Net Cash From Financing Activities		 0.58 -1.27 -0.87 1.86 102 201 213 64 -6.22 -9.67 34
Net Cash From Continuing Financing Activities		 0.58 -1.27 -0.87 1.86 102 201 213 64 -6.22 -9.67 34
Issuance of Debt		 - 0.00 0.00 5.00 - 0.00 0.00 65 - 0.00 122
Repayment of Debt		 -0.07 -0.08 -0.11 -1.32 -5.62 -0.16 -0.15 -0.14 -0.04 0.00 -71
Payment of Dividends		 - - - - - - 0.00 0.00 -3.53 -5.56 -5.90
Other Financing Activities, Net		 0.65 -1.19 -0.77 -1.82 -18 -27 -0.63 -0.89 -2.65 -4.11 -11
Effect of Exchange Rate Changes		 0.02 -0.02 0.00 - 0.03 0.19 0.06 -0.36 -0.02 -0.06 0.15
Cash Interest Paid		 0.03 0.01 0.02 0.04 0.04 0.00 0.00 5.03 9.05 9.23 8.92

Quarterly Cash Flow Statements for eHealth

This table details how cash moves in and out of eHealth's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 59 -49 -62 -25 82 -55 -2.83 11 1.39 -5.89 -12
Net Cash From Operating Activities		 71 -32 -29 -28 77 -41 -25 -36 36 -4.96 -11
Net Cash From Continuing Operating Activities		 71 -32 -29 -28 77 -41 -25 -36 36 -4.96 -11
Net Income / (Loss) Continuing Operations		 -17 -28 -42 97 1.95 -17 -32 87 -4.71 -24 -36
Consolidated Net Income / (Loss)		 -17 -28 -42 97 1.95 -17 -32 87 -4.71 -24 -36
Depreciation Expense		 0.53 0.48 0.47 0.50 0.47 0.47 0.45 0.50 0.49 0.49 0.44
Amortization Expense		 3.87 3.80 3.35 3.33 3.46 3.01 2.69 2.72 2.77 2.80 2.93
Non-Cash Adjustments to Reconcile Net Income		 9.58 5.74 2.84 19 5.01 -2.77 -7.40 41 1.08 -3.93 -10
Changes in Operating Assets and Liabilities, net		 74 -14 6.52 -148 66 -25 11 -167 36 19 32
Net Cash From Investing Activities		 -10 -13 -33 7.99 5.47 -10 24 6.38 -34 1.93 -1.20
Net Cash From Continuing Investing Activities		 -10 -13 -33 7.99 5.47 -10 24 6.38 -34 1.93 -1.20
Purchase of Property, Leasehold Improvements and Equipment		 -2.49 -2.85 -4.19 -3.32 -3.43 -5.84 -3.62 -2.42 -2.31 -2.68 -1.92
Purchase of Investment Securities		 -14 -24 -48 -11 -27 -35 -12 - -36 -13 -11
Sale and/or Maturity of Investments		 6.00 13 20 22 36 30 39 8.80 3.50 18 12
Net Cash From Financing Activities		 -1.26 -2.98 -0.45 -4.98 -0.70 -3.84 -1.28 40 -0.16 -3.03 -0.05
Net Cash From Continuing Financing Activities		 -1.26 -2.98 -0.45 -4.98 -0.70 -3.84 -1.28 40 -0.16 -3.03 -0.05
Other Financing Activities, Net		 -1.26 -0.24 -0.45 -1.12 -0.70 -0.94 -1.28 -8.36 -0.16 0.05 -0.05
Effect of Exchange Rate Changes		 0.05 -0.03 0.10 -0.18 0.00 -0.01 0.06 0.09 0.14 0.17 0.12

Annual Balance Sheets for eHealth

This table presents eHealth's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 113 109 359 439 742 1,040 1,149 1,113 1,113 1,155 1,262
Cash and Due from Banks		 63 62 40 13 23 44 82 144 116 39 74
Restricted Cash		 - - - - 3.35 3.35 3.24 3.24 3.09 3.09 3.09
Trading Account Securities		 - - - - 0.00 50 41 0.00 5.93 43 3.50
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 7.36 5.61 4.71 7.68 11 15 12 5.50 4.86 4.44 4.53
Other Assets		 20 19 292 366 654 880 1,011 959 984 1,066 1,178
Total Liabilities & Shareholders' Equity		 113 109 359 439 742 1,040 1,149 1,113 1,113 1,155 1,262
Total Liabilities		 37 31 72 136 214 202 167 198 209 229 289
Short-Term Debt		 3.01 5.11 3.25 5.69 25 37 14 6.73 7.20 23 28
Accrued Interest Payable		 11 7.16 4.69 11 17 18 42 30 20 17 16
Other Short-Term Payables		 18 16 18 44 72 30 20 24 51 56 55
Long-Term Debt		 - - 0.00 5.00 - - 0.00 66 68 68 113
Other Long-Term Liabilities		 4.96 3.37 47 71 101 118 92 72 63 65 77
Commitments & Contingencies		 0.00 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - 0.00 233 263 298 338 382
Total Equity & Noncontrolling Interests		 76 78 287 303 527 838 750 651 606 588 592
Total Preferred & Common Equity		 76 78 287 303 527 838 750 651 606 588 592
Total Common Equity		 76 78 287 303 527 838 750 651 606 588 592
Common Stock		 267 273 282 298 455 721 756 777 799 773 762
Retained Earnings		 9.50 4.62 205 205 272 316 193 74 7.28 15 30
Treasury Stock		 -200 -200 -200 -200 -200 -200 -200 -200 -200 -200 -200
Accumulated Other Comprehensive Income / (Loss)		 0.19 0.18 0.20 0.13 0.12 0.35 0.39 -0.07 -0.08 -0.23 -0.06

Quarterly Balance Sheets for eHealth

This table presents eHealth's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 1,026 1,096 1,039 1,002 1,137 1,080 1,047 1,201 1,158 1,114
Cash and Due from Banks		 152 175 126 64 121 66 63 75 70 57
Restricted Cash		 3.09 3.09 3.09 3.09 3.09 3.09 3.09 3.09 2.63 2.63
Trading Account Securities		 8.47 14 25 54 34 39 12 36 31 31
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 5.43 4.23 4.36 4.77 4.12 5.22 4.94 4.60 4.11 3.72
Other Assets		 857 899 880 876 974 966 964 1,083 1,050 1,019
Total Liabilities & Shareholders' Equity		 1,026 1,096 1,039 1,002 1,137 1,080 1,047 1,201 1,158 1,114
Total Liabilities		 178 205 173 176 208 166 163 231 211 201
Short-Term Debt		 7.00 74 74 5.41 76 75 6.22 5.59 2.95 4.34
Accrued Interest Payable		 7.42 9.40 7.84 9.21 9.07 4.05 5.56 4.73 2.78 2.78
Other Short-Term Payables		 39 62 35 39 58 31 39 34 26 29
Long-Term Debt		 67 0.00 0.00 69 0.00 0.00 69 114 115 115
Other Long-Term Liabilities		 57 59 56 53 64 56 42 73 65 49
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 289 307 317 327 348 359 370 394 406 419
Total Equity & Noncontrolling Interests		 560 583 549 499 582 555 514 576 541 494
Total Preferred & Common Equity		 560 583 549 499 582 555 514 576 541 494
Total Common Equity		 560 583 549 499 582 555 514 576 541 494
Common Stock		 794 803 808 813 777 767 758 764 752 741
Retained Earnings		 -34 -20 -59 -113 5.27 -12 -44 12 -12 -48
Treasury Stock		 -200 -200 -200 -200 -200 -200 -200 -200 -200 -200
Accumulated Other Comprehensive Income / (Loss)		 -0.13 -0.06 -0.09 0.13 -0.27 -0.26 -0.18 0.06 0.23 0.35

Annual Metrics And Ratios for eHealth

This table displays calculated financial ratios and metrics derived from eHealth's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 18,117,464.00 18,341,531.00 18,622,299.00 19,406,466.00 23,098,198.00 25,897,314.00 26,388,112.00 27,422,321.00 28,364,821.00 - 30,764,785.00
DEI Adjusted Shares Outstanding		 18,117,464.00 18,341,531.00 18,622,299.00 19,406,466.00 23,098,198.00 25,897,314.00 26,388,112.00 27,422,321.00 28,364,821.00 - 30,764,785.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.26 0.02 1.37 0.01 2.90 1.76 -3.96 -3.24 -0.99 - 1.30
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 5.49% 2.00% -1.35% 31.82% 101.36% 15.13% -7.79% -25.98% 11.11% 17.96% 4.22%
EBITDA Growth		 186.39% 276.00% -149.52% 326.76% 869.75% -25.96% -260.79% 17.09% 77.44% 242.81% 141.69%
EBIT Growth		 16.07% 149.96% -434.82% 126.99% 3,091.26% -33.68% -334.29% 12.77% 63.70% 130.99% 348.98%
NOPAT Growth		 16.43% 105.46% -3,162.29% 102.81% 34,967.77% -30.31% -294.81% 12.77% 63.70% 123.06% 487.89%
Net Income Growth		 70.61% 106.38% 8,263.82% -99.05% 27,653.94% -32.05% -329.65% 15.00% 68.20% 135.65% 298.17%
EPS Growth		 70.45% 107.69% 6,550.00% -99.25% 27,200.00% -38.46% -373.21% 5.01% 45.64% 49.79% 71.43%
Operating Cash Flow Growth		 669.87% -70.19% -480.63% 79.22% -2,113.37% -50.87% -50.77% 83.48% 75.09% -174.45% -38.00%
Free Cash Flow Firm Growth		 -107.42% 22.43% -6,878.38% 88.90% -627.30% -60.60% 24.30% 67.38% 70.84% -61.98% -82.68%
Invested Capital Growth		 -0.01% 4.13% 250.50% 8.25% 75.80% 58.50% 13.88% -0.88% -0.82% 3.96% 9.54%
Revenue Q/Q Growth		 2.80% -0.01% 20.92% 25.95% 49.16% -1.43% -8.61% -11.95% 14.55% 14.93% 1.94%
EBITDA Q/Q Growth		 179.88% 44.16% 88.14% 177.41% 1,035.39% -38.56% -2,198.73% 39.15% 61.93% 220.88% 21.44%
EBIT Q/Q Growth		 19.23% 296.86% 75.38% 113.91% 169,702.08% -44.38% -958.23% 34.30% 45.47% 130.22% 30.06%
NOPAT Q/Q Growth		 19.56% 121.52% 75.38% 101.45% 30,117.35% -38.29% -939.70% 34.30% 45.47% 122.48% -16.82%
Net Income Q/Q Growth		 59.96% 224.59% 280.07% -89.03% 1,517.58% -38.91% -745.14% 37.32% 52.77% 128.54% -20.46%
EPS Q/Q Growth		 58.73% 300.00% 272.73% -95.65% 841.38% -46.50% -410.00% 30.68% 30.29% 54.58% -312.50%
Operating Cash Flow Q/Q Growth		 63.20% -59.20% -53.67% 30.39% -205.10% -59.23% -3.43% 75.70% -182.46% 23.76% -48.58%
Free Cash Flow Firm Q/Q Growth		 -184.15% 56.82% -1,356.56% 88.66% -1.29% -1.27% 6.52% -4.70% -51.00% -366.26% -341.29%
Invested Capital Q/Q Growth		 -10.59% -12.87% 250.38% 12.34% 22.70% 9.70% -1.71% 2.71% 6.09% 12.96% 16.13%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 1.16% 4.29% -2.16% 3.71% 17.86% 11.49% -20.03% -22.44% -4.56% 5.52% 12.79%
EBIT Margin		 -2.98% 1.46% -4.96% 1.01% 16.08% 9.26% -23.54% -27.74% -9.06% 2.38% 10.26%
Profit (Net Income) Margin		 -2.51% 0.16% 13.33% 0.10% 13.21% 7.80% -19.42% -22.31% -6.38% 1.93% 7.37%
Tax Burden Percent		 84.96% 7.65% -307.45% 7.29% 80.11% 84.18% 83.57% 83.39% 92.22% 52.08% 68.19%
Interest Burden Percent		 99.20% 140.70% 87.49% 129.60% 102.57% 100.00% 98.74% 96.42% 76.40% 155.59% 105.38%
Effective Tax Rate		 0.00% 92.35% 0.00% 92.71% 19.89% 15.82% 0.00% 0.00% 0.00% 47.92% 31.81%
Return on Invested Capital (ROIC)		 -4.98% 0.27% -3.55% 0.06% 15.07% 6.37% -9.47% -7.79% -2.85% 0.65% 3.56%
ROIC Less NNEP Spread (ROIC-NNEP)		 -22.97% 2.43% 763.20% 0.85% 24.57% 6.37% -71.96% -34.31% -3.10% 4.95% 5.32%
Return on Net Nonoperating Assets (RNNOA)		 -1.38% 0.13% 17.51% 0.02% 1.04% 0.29% -2.00% -1.57% -0.25% 0.45% 0.65%
Return on Equity (ROE)		 -6.35% 0.39% 13.96% 0.08% 16.11% 6.66% -11.47% -9.36% -3.10% 1.10% 4.22%
Cash Return on Invested Capital (CROIC)		 -4.97% -3.78% -114.76% -7.86% -39.90% -38.89% -22.45% -6.91% -2.03% -3.24% -5.54%
Operating Return on Assets (OROA)		 -5.14% 2.54% -4.04% 0.64% 13.79% 6.06% -11.56% -9.76% -3.60% 1.09% 4.61%
Return on Assets (ROA)		 -4.33% 0.27% 10.87% 0.06% 11.33% 5.10% -9.54% -7.84% -2.54% 0.89% 3.31%
Return on Common Equity (ROCE)		 -6.35% 0.39% 13.96% 0.08% 16.11% 6.66% -10.01% -6.91% -2.15% 0.72% 2.62%
Return on Equity Simple (ROE_SIMPLE)		 -6.23% 0.39% 8.87% 0.08% 12.69% 5.43% -13.93% -13.63% -4.66% 1.71% 6.77%
Net Operating Profit after Tax (NOPAT)		 -3.96 0.22 -6.62 0.19 65 45 -89 -77 -28 6.46 38
NOPAT Margin		 -2.09% 0.11% -3.47% 0.07% 12.88% 7.80% -16.48% -19.42% -6.34% 1.24% 6.99%
Net Nonoperating Expense Percent (NNEP)		 17.99% -2.16% -766.75% -0.79% -9.50% 0.00% 62.49% 26.52% 0.24% -4.31% -1.75%
SG&A Expenses to Revenue		 39.87% 37.35% 34.54% 32.99% 29.68% 35.92% 50.49% 49.05% 39.07% 36.61% 33.36%
Operating Expenses to Revenue		 102.98% 98.54% 104.96% 98.99% 83.92% 90.74% 123.54% 127.74% 109.06% 97.62% 89.74%
Earnings before Interest and Taxes (EBIT)		 -5.65 2.82 -9.45 2.55 81 54 -126 -110 -40 12 56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.21 8.30 -4.11 9.32 90 67 -108 -89 -20 29 69
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.37 2.52 1.13 2.46 4.21 2.18 0.90 0.20 0.41 0.47 0.24
Price to Tangible Book Value (P/TBV)		 3.43 3.56 1.22 2.97 4.65 2.32 0.90 0.20 0.41 0.47 0.24
Price to Revenue (P/Rev)		 0.95 1.01 1.70 2.97 4.38 3.14 1.25 0.33 0.56 0.53 0.26
Price to Earnings (P/E)		 0.00 642.56 12.72 3,093.76 33.18 40.23 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.16% 7.86% 0.03% 3.01% 2.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.52 1.68 0.99 2.37 4.02 2.08 0.84 0.33 0.51 0.65 0.53
Enterprise Value to Revenue (EV/Rev)		 0.64 0.72 1.50 2.96 4.38 3.12 1.55 0.81 1.14 1.28 1.08
Enterprise Value to EBITDA (EV/EBITDA)		 54.85 16.70 0.00 79.72 24.52 27.17 0.00 0.00 0.00 23.15 8.46
Enterprise Value to EBIT (EV/EBIT)		 0.00 49.12 0.00 291.33 27.23 33.68 0.00 0.00 0.00 53.63 10.55
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 641.80 0.00 3,996.49 34.00 40.01 0.00 0.00 0.00 102.99 15.47
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.84 33.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.04 0.07 0.01 0.04 0.05 0.04 0.01 0.08 0.08 0.10 0.15
Long-Term Debt to Equity		 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.07 0.07 0.07 0.12
Financial Leverage		 0.06 0.05 0.02 0.02 0.04 0.05 0.03 0.05 0.08 0.09 0.12
Leverage Ratio		 1.47 1.44 1.28 1.35 1.42 1.31 1.20 1.19 1.22 1.24 1.27
Compound Leverage Factor		 1.46 2.03 1.12 1.75 1.46 1.31 1.19 1.15 0.94 1.93 1.34
Debt to Total Capital		 3.79% 6.18% 1.12% 3.41% 4.45% 4.22% 1.38% 7.38% 7.66% 9.03% 12.67%
Short-Term Debt to Total Capital		 3.79% 6.18% 1.12% 1.81% 4.45% 4.22% 1.38% 0.68% 0.74% 2.30% 2.54%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.59% 0.00% 0.00% 0.00% 6.70% 6.92% 6.73% 10.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 23.36% 26.67% 30.44% 33.16% 34.27%
Common Equity to Total Capital		 96.21% 93.82% 98.88% 96.59% 95.55% 95.78% 75.26% 65.95% 61.90% 57.81% 53.06%
Debt to EBITDA		 1.36 0.62 -0.79 1.15 0.27 0.55 -0.13 -0.82 -3.72 3.20 2.03
Net Debt to EBITDA		 -27.04 -6.83 9.01 -0.26 -0.03 -0.15 0.66 0.84 2.18 1.73 0.93
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.54 0.00 0.00 0.00 -0.74 -3.37 2.38 1.63
Debt to NOPAT		 -0.76 23.66 -0.49 57.47 0.38 0.81 -0.16 -0.94 -2.67 14.22 3.72
Net Debt to NOPAT		 15.09 -262.28 5.60 -12.91 -0.03 -0.22 0.81 0.97 1.56 7.68 1.70
Long-Term Debt to NOPAT		 0.00 0.00 0.00 26.89 0.00 0.00 0.00 -0.86 -2.42 10.59 2.97
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.78% 26.15% 30.87% 34.73% 37.88%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.95 -3.06 -214 -24 -173 -277 -210 -68 -20 -32 -59
Operating Cash Flow to CapEx		 457.14% 109.58% -306.05% -29.83% -423.73% -454.03% -779.70% -173.28% -62.08% -142.86% -165.57%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -248.43 -8.98 -1.82 -2.90 -5.49
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -192.45 -3.52 -0.61 -1.65 -2.36
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -217.13 -5.56 -1.59 -2.80 -3.78
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.72 1.74 0.82 0.63 0.86 0.65 0.49 0.35 0.40 0.46 0.45
Fixed Asset Turnover		 22.29 29.81 36.98 40.58 55.62 46.39 40.23 45.18 85.27 112.08 121.15
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 79 83 290 314 552 874 996 987 979 1,018 1,115
Invested Capital Turnover		 2.39 2.38 1.02 0.83 1.17 0.82 0.57 0.40 0.45 0.52 0.51
Increase / (Decrease) in Invested Capital		 -0.01 3.28 207 24 238 323 121 -8.76 -8.07 39 97
Enterprise Value (EV)		 121 139 286 743 2,217 1,818 834 321 502 666 588
Market Capitalization		 181 195 323 746 2,219 1,829 673 133 247 279 142
Book Value per Share		 $4.22 $4.23 $15.39 $15.62 $22.82 $32.34 $28.40 $23.74 $21.37 $19.86 $19.23
Tangible Book Value per Share		 $2.91 $2.99 $14.23 $12.92 $20.65 $30.46 $28.40 $23.74 $21.37 $19.86 $19.23
Total Capital		 79 83 290 314 552 874 996 987 979 1,018 1,115
Total Debt		 3.01 5.11 3.25 11 25 37 14 73 75 92 141
Total Long-Term Debt		 0.00 0.00 0.00 5.00 0.00 0.00 0.00 66 68 68 113
Net Debt		 -60 -57 -37 -2.40 -2.27 -10 -71 -75 -44 50 64
Capital Expenditures (CapEx)		 3.00 3.73 5.08 11 17 24 21 16 11 13 15
Net Nonoperating Expense (NNE)		 0.81 -0.09 -32 -0.06 -1.67 0.00 16 11 0.18 -3.59 -2.04
Net Nonoperating Obligations (NNO)		 3.01 5.11 3.25 11 25 37 14 73 75 92 141
Total Depreciation and Amortization (D&A)		 7.86 5.48 5.34 6.77 8.99 13 19 21 20 16 14
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.26) ($0.27) ($1.37) $0.01 $2.90 $1.75 ($4.59) ($4.36) ($2.37) ($1.19) ($0.34)
Adjusted Weighted Average Basic Shares Outstanding		 18.01M 18.27M 18.51M 19.29M 23.08M 26.03M 26.78M 27.36M 28.02M 29.34M 30.48M
Adjusted Diluted Earnings per Share		 ($0.26) ($0.27) ($1.37) $0.01 $2.73 $1.68 ($4.59) ($4.36) ($2.37) ($1.19) ($0.34)
Adjusted Weighted Average Diluted Shares Outstanding		 18.01M 18.27M 18.51M 20.41M 24.54M 27.01M 26.78M 27.36M 28.02M 29.34M 30.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 18.15M 18.36M 18.94M 22.55M 23.46M 25.93M 26.77M 27.61M 28.94M 29.94M 31.07M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.78 1.77 -6.18 12 85 45 -53 -64 -28 11 39
Normalized NOPAT Margin		 -0.41% 0.91% -3.24% 4.68% 16.69% 7.70% -9.81% -15.97% -6.34% 2.19% 7.25%
Pre Tax Income Margin		 -2.96% 2.05% -4.34% 1.32% 16.50% 9.26% -23.24% -26.75% -6.92% 3.70% 10.81%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -149.69 -14.47 -3.65 1.11 5.18
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -104.78 -10.13 -2.55 0.58 3.53
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -174.38 -16.50 -4.63 -0.04 3.76
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -129.47 -12.16 -3.54 -0.57 2.11
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12.52% 55.29% 14.73%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12.52% 55.29% 14.73%

Quarterly Metrics And Ratios for eHealth

This table displays calculated financial ratios and metrics derived from eHealth's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 28,938,509.00 29,123,456.00 29,405,418.00 - 29,942,604.00 30,326,646.00 30,557,181.00 30,764,785.00 31,073,002.00 31,741,018.00 32,032,654.00
DEI Adjusted Shares Outstanding		 28,938,509.00 29,123,456.00 29,405,418.00 - 29,942,604.00 30,326,646.00 30,557,181.00 30,764,785.00 31,073,002.00 31,741,018.00 32,032,654.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.59 -0.96 -1.44 - 0.07 -0.57 -1.04 2.83 -0.15 -0.74 -1.12
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 26.72% -1.63% -10.25% 27.67% 22.53% -7.26% -7.32% 3.30% -23.98% -49.50% -66.78%
EBITDA Growth		 19.35% -11.84% -12.70% 85.71% 137.29% 17.37% 3.46% 10.78% -160.08% -28.74% -15.64%
EBIT Growth		 18.66% -6.71% -9.10% 94.63% 110.38% 17.58% 4.67% 11.71% -421.53% -24.10% -15.06%
NOPAT Growth		 18.66% -6.71% -9.10% 92.41% 107.76% 17.58% 4.67% -9.52% -530.07% -24.10% -15.06%
Net Income Growth		 14.56% -19.01% -14.71% 86.78% 111.48% 37.79% 25.39% -10.57% -341.74% -35.62% -13.34%
EPS Growth		 4.95% -12.71% -8.93% 95.33% 65.63% 26.32% 20.22% -17.06% -75.76% -20.41% -7.53%
Operating Cash Flow Growth		 16.38% -241.34% -18.65% 17.14% 8.99% -28.03% 13.56% -29.96% -53.62% 87.97% 55.59%
Free Cash Flow Firm Growth		 -120.17% -135.00% -220.75% -0.44% -395.08% -870.21% -761.19% -115.90% -120.85% -46.52% -20.05%
Invested Capital Growth		 -0.66% -1.54% -2.36% 3.96% 4.25% 5.23% 6.56% 9.54% 8.28% 7.69% 7.55%
Revenue Q/Q Growth		 -63.17% -30.11% -11.84% 462.63% -64.65% -47.10% -11.89% 527.09% -73.99% -64.86% -42.05%
EBITDA Q/Q Growth		 -126.62% -62.62% -59.18% 369.53% -94.66% -460.31% -85.98% 409.29% -102.90% -672.09% -67.06%
EBIT Q/Q Growth		 -136.66% -48.69% -49.50% 338.83% -98.05% -1,281.02% -72.92% 379.85% -105.63% -355.82% -60.33%
NOPAT Q/Q Growth		 -128.75% -48.69% -49.50% 401.06% -98.84% -1,679.66% -72.92% 385.73% -105.51% -355.82% -60.33%
Net Income Q/Q Growth		 -132.54% -64.67% -51.86% 329.52% -98.00% -992.21% -82.15% 375.10% -105.41% -400.53% -52.23%
EPS Q/Q Growth		 -164.00% -38.54% -37.59% 260.11% -111.26% -196.97% -48.98% 266.44% -123.87% -103.45% -33.05%
Operating Cash Flow Q/Q Growth		 311.95% -145.48% 9.01% 5.54% 378.80% -153.43% 38.57% -42.02% 199.49% -113.85% -126.88%
Free Cash Flow Firm Q/Q Growth		 -113.77% 14.42% -51.21% 658.61% -168.49% -67.70% -34.22% 89.69% -851.33% -11.26% -9.97%
Invested Capital Q/Q Growth		 -1.46% -2.61% -4.10% 12.96% -1.19% -1.70% -2.89% 16.13% -2.33% -2.24% -3.01%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 -18.10% -42.11% -76.02% 36.42% 5.51% -37.51% -79.18% 39.05% -4.35% -95.62% -275.67%
EBIT Margin		 -22.98% -48.90% -82.91% 35.20% 1.95% -43.45% -85.29% 38.06% -8.23% -106.77% -295.41%
Profit (Net Income) Margin		 -18.84% -44.39% -76.46% 31.19% 1.77% -29.77% -61.55% 27.00% -5.61% -79.95% -210.03%
Tax Burden Percent		 92.66% 98.23% 95.75% 88.24% 52.33% 72.33% 73.82% 71.47% 77.62% 76.91% 72.22%
Interest Burden Percent		 88.46% 92.42% 96.31% 100.43% 173.30% 94.72% 97.77% 99.27% 87.85% 97.36% 98.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 11.76% 47.67% 0.00% 0.00% 28.53% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -7.66% -16.62% -28.86% 16.21% 0.56% -16.94% -34.19% 13.86% -2.84% -35.51% -94.11%
ROIC Less NNEP Spread (ROIC-NNEP)		 -11.05% -25.34% -42.61% 16.72% 1.66% -16.44% -35.46% 13.31% -2.71% -37.11% -94.68%
Return on Net Nonoperating Assets (RNNOA)		 -0.90% -2.13% -3.79% 1.52% 0.14% -1.37% -3.11% 1.63% -0.28% -3.84% -10.30%
Return on Equity (ROE)		 -8.56% -18.75% -32.65% 17.74% 0.70% -18.31% -37.30% 15.49% -3.12% -39.35% -104.41%
Cash Return on Invested Capital (CROIC)		 -1.89% -1.20% -0.76% -3.24% -1.65% -1.45% -1.44% -5.54% -4.91% -4.86% -5.07%
Operating Return on Assets (OROA)		 -9.72% -21.50% -37.08% 16.17% 0.94% -22.03% -44.36% 17.10% -3.64% -46.55% -123.97%
Return on Assets (ROA)		 -7.97% -19.51% -34.19% 14.33% 0.86% -15.10% -32.01% 12.13% -2.48% -34.86% -88.14%
Return on Common Equity (ROCE)		 -5.79% -12.34% -20.64% 11.58% 0.45% -11.36% -22.10% 9.62% -1.90% -23.17% -58.54%
Return on Equity Simple (ROE_SIMPLE)		 -4.34% -5.43% -7.06% 0.00% 4.98% 7.13% 9.79% 0.00% 5.80% 5.03% 4.65%
Net Operating Profit after Tax (NOPAT)		 -15 -22 -32 97 1.13 -18 -31 88 -4.84 -22 -35
NOPAT Margin		 -16.09% -34.23% -58.04% 31.06% 1.02% -30.42% -59.70% 27.20% -5.76% -74.74% -206.79%
Net Nonoperating Expense Percent (NNEP)		 3.39% 8.72% 13.75% -0.50% -1.10% -0.51% 1.27% 0.55% -0.13% 1.60% 0.57%
SG&A Expenses to Revenue		 42.97% 42.51% 53.40% 30.60% 37.28% 36.67% 47.38% 29.19% 30.24% 39.92% 63.67%
Operating Expenses to Revenue		 122.98% 148.90% 182.91% 64.81% 98.05% 143.45% 185.29% 61.94% 108.23% 206.77% 395.41%
Earnings before Interest and Taxes (EBIT)		 -21 -31 -46 110 2.15 -25 -44 123 -6.91 -32 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -27 -42 114 6.08 -22 -41 126 -3.66 -28 -47
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.30 0.24 0.24 0.47 0.34 0.24 0.26 0.24 0.07 0.09 0.05
Price to Tangible Book Value (P/TBV)		 0.30 0.24 0.24 0.47 0.34 0.24 0.26 0.24 0.07 0.09 0.05
Price to Revenue (P/Rev)		 0.38 0.29 0.26 0.53 0.37 0.25 0.25 0.26 0.08 0.10 0.05
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 97.48 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.03% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.39 0.42 0.50 0.65 0.50 0.50 0.53 0.53 0.44 0.47 0.49
Enterprise Value to Revenue (EV/Rev)		 0.82 0.86 1.00 1.28 0.92 0.92 0.96 1.08 0.92 1.02 1.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 23.15 9.77 8.91 8.94 8.46 7.95 9.33 10.66
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 53.63 14.17 12.20 11.94 10.55 10.18 12.30 14.79
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 102.99 20.22 14.12 11.20 15.47 14.92 19.14 22.87
Enterprise Value to Operating Cash Flow (EV/OCF)		 115.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.08 0.09 0.09 0.10 0.08 0.08 0.09 0.15 0.12 0.12 0.13
Long-Term Debt to Equity		 0.00 0.00 0.08 0.07 0.00 0.00 0.08 0.12 0.12 0.12 0.13
Financial Leverage		 0.08 0.08 0.09 0.09 0.08 0.08 0.09 0.12 0.10 0.10 0.11
Leverage Ratio		 1.22 1.20 1.21 1.24 1.23 1.19 1.20 1.27 1.23 1.20 1.20
Compound Leverage Factor		 1.08 1.11 1.17 1.25 2.13 1.13 1.17 1.26 1.08 1.17 1.18
Debt to Total Capital		 7.72% 7.84% 8.28% 9.03% 7.57% 7.57% 7.88% 12.67% 10.96% 11.04% 11.61%
Short-Term Debt to Total Capital		 7.72% 7.84% 0.60% 2.30% 7.57% 7.57% 0.65% 2.54% 0.51% 0.28% 0.42%
Long-Term Debt to Total Capital		 0.00% 0.00% 7.68% 6.73% 0.00% 0.00% 7.23% 10.13% 10.45% 10.76% 11.19%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 31.87% 33.75% 36.31% 33.16% 34.60% 36.30% 38.57% 34.27% 36.17% 38.16% 40.60%
Common Equity to Total Capital		 60.41% 58.42% 55.42% 57.81% 57.83% 56.13% 53.55% 53.06% 52.87% 50.80% 47.80%
Debt to EBITDA		 -4.59 -3.87 -3.14 3.20 1.49 1.34 1.32 2.03 2.00 2.20 2.55
Net Debt to EBITDA		 6.39 2.93 -0.31 1.73 -0.94 0.10 0.17 0.93 0.69 0.85 1.27
Long-Term Debt to EBITDA		 0.00 0.00 -2.91 2.38 0.00 0.00 1.21 1.63 1.90 2.14 2.45
Debt to NOPAT		 -3.01 -2.82 -2.59 14.22 3.08 2.13 1.66 3.72 3.75 4.51 5.46
Net Debt to NOPAT		 4.19 2.14 -0.26 7.68 -1.94 0.17 0.21 1.70 1.29 1.74 2.73
Long-Term Debt to NOPAT		 0.00 0.00 -2.41 10.59 0.00 0.00 1.52 2.97 3.57 4.40 5.26
Noncontrolling Interest Sharing Ratio		 32.35% 34.18% 36.78% 34.73% 36.01% 37.98% 40.76% 37.88% 39.06% 41.12% 43.93%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.06 -6.90 -10 58 -40 -67 -90 -9.26 -88 -98 -108
Operating Cash Flow to CapEx		 2,841.81% -1,127.61% -699.05% -832.44% 2,251.05% -705.19% -698.68% -1,487.96% 1,551.63% -184.68% -586.13%
Free Cash Flow to Firm to Interest Expense		 -2.87 -2.42 -3.65 22.05 -15.07 -28.50 -37.67 -2.74 -21.84 -24.18 -25.80
Operating Cash Flow to Interest Expense		 25.19 -11.30 -10.24 -10.47 29.12 -17.55 -10.62 -10.63 8.86 -1.22 -2.69
Operating Cash Flow Less CapEx to Interest Expense		 24.30 -12.30 -11.71 -11.73 27.83 -20.04 -12.14 -11.35 8.29 -1.88 -3.15
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.42 0.44 0.45 0.46 0.49 0.51 0.52 0.45 0.44 0.44 0.42
Fixed Asset Turnover		 99.96 97.96 88.95 112.08 129.70 112.18 109.78 121.15 118.54 104.64 104.72
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 965 940 901 1,018 1,006 989 960 1,115 1,089 1,065 1,033
Invested Capital Turnover		 0.48 0.49 0.50 0.52 0.55 0.56 0.57 0.51 0.49 0.48 0.46
Increase / (Decrease) in Invested Capital		 -6.45 -15 -22 39 41 49 59 97 83 76 72
Enterprise Value (EV)		 378 393 455 666 500 497 511 588 475 499 502
Market Capitalization		 174 132 120 279 200 132 132 142 40 47 23
Book Value per Share		 $20.14 $18.85 $16.98 $19.86 $19.42 $18.30 $16.83 $19.23 $18.53 $17.04 $15.41
Tangible Book Value per Share		 $20.14 $18.85 $16.98 $19.86 $19.42 $18.30 $16.83 $19.23 $18.53 $17.04 $15.41
Total Capital		 965 940 901 1,018 1,006 989 960 1,115 1,089 1,065 1,033
Total Debt		 74 74 75 92 76 75 76 141 119 118 120
Total Long-Term Debt		 0.00 0.00 69 68 0.00 0.00 69 113 114 115 115
Net Debt		 -104 -56 7.44 50 -48 5.83 9.46 64 41 45 60
Capital Expenditures (CapEx)		 2.49 2.85 4.19 3.32 3.43 5.84 3.62 2.42 2.31 2.68 1.92
Net Nonoperating Expense (NNE)		 2.48 6.40 10 -0.42 -0.82 -0.38 0.95 0.64 -0.13 1.54 0.55
Net Nonoperating Obligations (NNO)		 74 74 75 92 76 75 76 141 119 118 120
Total Depreciation and Amortization (D&A)		 4.41 4.28 3.83 3.83 3.93 3.47 3.14 3.21 3.26 3.29 3.38
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.96) ($1.33) ($1.83) $2.93 ($0.33) ($0.98) ($1.46) $2.43 ($0.58) ($1.18) ($1.57)
Adjusted Weighted Average Basic Shares Outstanding		 28.91M 29.23M 29.49M 29.34M 30.00M 30.40M 30.63M 30.48M 31.13M 31.78M 32.13M
Adjusted Diluted Earnings per Share		 ($0.96) ($1.33) ($1.83) $2.93 ($0.33) ($0.98) ($1.46) $2.43 ($0.58) ($1.18) ($1.57)
Adjusted Weighted Average Diluted Shares Outstanding		 28.91M 29.23M 29.49M 29.34M 30.00M 30.40M 30.63M 30.48M 31.13M 31.78M 32.13M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 29.12M 29.41M 29.63M 29.94M 30.33M 30.56M 30.76M 31.07M 31.74M 32.03M 32.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -10 -19 -32 97 1.13 -17 -30 88 -0.38 -22 -35
Normalized NOPAT Margin		 -11.19% -30.86% -57.96% 31.07% 1.02% -28.56% -59.08% 27.20% -0.45% -74.60% -206.79%
Pre Tax Income Margin		 -20.33% -45.19% -79.85% 35.35% 3.37% -41.16% -83.39% 37.78% -7.23% -103.95% -290.81%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.38 -10.81 -16.11 41.63 0.81 -10.81 -18.42 36.34 -1.71 -7.77 -12.09
NOPAT to Interest Expense		 -5.16 -7.57 -11.28 36.74 0.42 -7.57 -12.89 25.98 -1.20 -5.44 -8.46
EBIT Less CapEx to Interest Expense		 -8.26 -11.82 -17.58 40.38 -0.48 -13.30 -19.94 35.63 -2.28 -8.43 -12.55
NOPAT Less CapEx to Interest Expense		 -6.05 -8.57 -12.74 35.48 -0.87 -10.06 -14.41 25.26 -1.77 -6.10 -8.92
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% -18.13% -15.33% 55.29% 0.00% 14.48% 11.38% 14.73% 0.00% 22.36% 26.47%
Augmented Payout Ratio		 0.00% -18.13% -15.33% 55.29% 0.00% 14.48% 11.38% 14.73% 0.00% 22.36% 26.47%

Financials Breakdown Chart

Key Financial Trends

eHealth’s second-quarter 2026 results show a sharp decline in revenue and continued losses, although cash-flow performance improved compared with the same period last year. Q2 revenue was $29.5 million, down from $58.4 million in Q2 2025 and $84.0 million in Q1 2026. The company reported a consolidated net loss of $23.6 million, compared with a $17.4 million loss a year earlier. After preferred dividends, the loss attributable to common shareholders widened to $37.5 million, or $1.18 per diluted share, versus a $29.8 million loss, or $0.98 per share, in Q2 2025.

The results remain highly seasonal. eHealth posted strong fourth-quarter profits in both 2024 and 2025, including $87.2 million of net income in Q4 2025, but generated losses in most first-, second- and third-quarter periods. Investors should therefore compare results with the same quarter of the prior year rather than rely only on sequential changes. Comparisons also require caution because several 2024 and 2025 figures in the dataset were subsequently restated.

  • Operating cash flow improved materially year over year. Q2 2026 operating cash flow was negative $5.0 million, an improvement from negative $41.2 million in Q2 2025 and negative $25.3 million in Q3 2025. Q1 2026 generated $35.8 million of operating cash flow, leaving first-half operating cash flow positive at approximately $30.8 million.
  • Investment activity supported liquidity in Q2. Sales and maturities of investments generated $17.6 million, exceeding the $13.0 million spent on investment securities and contributing to $1.9 million of net investing cash flow.
  • Cash and marketable securities remain a meaningful liquidity buffer. At June 30, 2026, eHealth held approximately $69.7 million in cash, $2.6 million in restricted cash and $31.4 million in trading securities, or roughly $103.7 million in combined liquid resources.
  • Q1 2026 showed a temporary improvement in profitability. The first-quarter net loss narrowed to $4.7 million from $17.4 million in Q1 2025, but the deterioration in Q2 indicates that the improvement was not yet consistent.
  • Revenue appears dependent on volatile non-interest income. Non-interest income fell from $60.8 million in Q2 2025 to $33.6 million in Q2 2026. Earlier periods also included large investment gains, suggesting that reported revenue and earnings may fluctuate substantially with investment results and seasonal enrollment activity.
  • Q2 revenue and earnings deteriorated sharply. Total revenue declined approximately 49% year over year, while the consolidated net loss increased by about 36%. The loss attributable to common shareholders increased even more because preferred stock dividends rose to $13.9 million from $12.4 million.
  • Operating expenses exceeded revenue by a wide margin. Q2 non-interest expenses totaled $61.0 million against $33.6 million of non-interest income. Marketing expense alone was $11.8 million, while other operating expenses were $49.2 million.
  • Debt and interest costs have increased since mid-2025. Long-term debt was $114.6 million at June 30, 2026, compared with no long-term debt reported at June 30, 2025. Quarterly interest expense rose to $4.1 million from $2.3 million a year earlier, adding pressure to profitability.
  • Cash declined during Q2 despite improved operating cash flow. Cash and equivalents fell from $75.1 million at March 31, 2026, to $69.7 million at June 30, while total cash and equivalents decreased by $5.9 million during the quarter. Financing activities used $3.0 million and capital expenditures used $2.7 million.
  • The balance sheet includes substantial redeemable noncontrolling interests. Redeemable noncontrolling interest increased to $406.3 million from $370.3 million in Q3 2025. Although not traditional debt, this obligation reduces the portion of reported equity economically attributable to common shareholders and complicates balance-sheet analysis.

Overall, the latest statements present a mixed picture for EHTH. Liquidity and second-quarter operating cash flow are better than a year ago, but the company remains dependent on seasonal and volatile revenue, is carrying more debt, and continues to report significant losses outside the strongest seasonal quarter. A sustained recovery would likely require revenue growth, tighter operating expenses and continued positive operating cash flow.

11/15/26 02:57 PM ETAI Generated. May Contain Errors.

eHealth Financials - Frequently Asked Questions

According to the most recent income statement we have on file, eHealth's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

eHealth's net income appears to be on a downward trend, with a most recent value of $40.04 million in 2025, compared with -$4.76 million in 2015. The previous period was $10.06 million in 2024. See where experts think eHealth is headed by visiting eHealth's forecast page.

Over the last 10 years, eHealth's total revenue changed from $189.54 million in 2015 to $543.25 million in 2025, a change of 186.6%.

In the past 12 quarters, eHealth's cash and equivalents has ranged from $57.31 million in Q3 2026 to $174.99 million in Q1 2024, and is currently $57.31 million as of their latest financial filing in Q3 2026.

eHealth had total debt of $141.28 million at the end of 2025, a 53.7% increase from 2024, and a 4,590.5% increase since 2015.

Over the last 10 years, eHealth's book value per share changed from 4.22 in 2015 to 19.23 in 2025, a change of 355.9%.


Related Companies

Financial statements for NASDAQ:EHTH last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...
TradeWins | Sponsoredtc pixel